Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Alnylam Pharmaceuticals

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 2002-01-01

Employees: -

Market Cap: $35.9B

Website: http://www.alnylam.com/

Clinical Trials

A Phase 1 Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers

Phase 1

Recruiting

Conditions: Obese or Overweight Healthy Volunteers

Interventions: Drug: ALN-4324
Drug: Placebo

First Posted Date: 2025-02-25

Last Posted Date: 2025-06-17

Lead Sponsor: Alnylam Pharmaceuticals

Target Recruit Count: 84

Registration Number: NCT06845202

Locations: 🇨🇦
Clinical Trial Site, Laval, Quebec, Canada

A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

Phase 3

Conditions: Transthyretin Amyloidosis (ATTR) With Cardiomyopathy

Interventions: Drug: Vutrisiran

First Posted Date: 2024-11-08

Last Posted Date: 2025-05-18

Lead Sponsor: Alnylam Pharmaceuticals

Target Recruit Count: 800

Registration Number: NCT06679946

Locations: 🇬🇧
Clinical Trial Site, Manchester, United Kingdom

A Study to Evaluate ALN-AGT01 RVR in Adult Healthy Volunteers

Phase 1

Recruiting

Conditions: Healthy Volunteers

Interventions: Drug: Placebo
Drug: ALN-AGT01 RVR

First Posted Date: 2024-11-05

Last Posted Date: 2025-05-14

Lead Sponsor: Alnylam Pharmaceuticals

Target Recruit Count: 78

Registration Number: NCT06675565

Locations: 🇨🇦
Clinical Trial Site, Montreal, Canada

A Study to Evaluate ALN-6400 in Adult Healthy Volunteers

Phase 1

Recruiting

Conditions: Healthy Volunteers

Interventions: Drug: ALN-6400
Drug: Placebo

First Posted Date: 2024-10-26

Last Posted Date: 2025-05-13

Lead Sponsor: Alnylam Pharmaceuticals

Target Recruit Count: 32

Registration Number: NCT06659640

Locations: 🇨🇦
Clinical Trial Site, Montreal, Canada

A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma

Phase 1

Recruiting

Conditions: Advanced Hepatocellular Carcinoma
Metastatic Hepatocellular Carcinoma

Interventions: Drug: ALN-BCAT
Drug: Pembrolizumab

First Posted Date: 2024-09-19

Last Posted Date: 2025-06-18

Lead Sponsor: Alnylam Pharmaceuticals

Target Recruit Count: 158

Registration Number: NCT06600321

Locations: 🇺🇸
Clinical Trial Site, San Antonio, Texas, United States

A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease

Phase 1

Recruiting

Conditions: Huntington's Disease

Interventions: Drug: ALN-HTT02
Drug: Placebo

First Posted Date: 2024-09-05

Last Posted Date: 2025-06-22

Lead Sponsor: Alnylam Pharmaceuticals

Target Recruit Count: 54

Registration Number: NCT06585449

Locations: 🇬🇧
Clinical Trial Site, Plymouth, United Kingdom

A Study to Evaluate Zilebesiran in Japanese Patients With Mild to Moderate Hypertension

Phase 1

Active, not recruiting

Conditions: Mild to Moderate Hypertension

Interventions: Drug: Placebo
Drug: Zilebesiran

First Posted Date: 2024-05-21

Last Posted Date: 2025-05-18

Lead Sponsor: Alnylam Pharmaceuticals

Target Recruit Count: 36

Registration Number: NCT06423352

Locations: 🇯🇵
Clinical Trial Site, Tokyo, Japan

A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy

Phase 2

Recruiting

Conditions: Cerebral Amyloid Angiopathy

Interventions: Drug: Placebo
Drug: ALN-APP

First Posted Date: 2024-05-01

Last Posted Date: 2025-06-17

Lead Sponsor: Alnylam Pharmaceuticals

Target Recruit Count: 200

Registration Number: NCT06393712

Locations: 🇬🇧
Clinical Trial Site, London, United Kingdom

Observational Study of Neurofilament Light Chain (NfL) as a Biomarker in Asymptomatic Carriers of the Transthyretin (TTR) Variants and Patients With Hereditary Transthyretin-mediated (hATTR) Amyloidosis With Polyneuropathy

Recruiting

Conditions: Asymptomatic Carrier State
Hereditary Amyloidosis, Transthyretin-Related

Interventions: Other: Standard of Care

First Posted Date: 2024-04-11

Last Posted Date: 2025-05-28

Lead Sponsor: Alnylam Pharmaceuticals

Target Recruit Count: 500

Registration Number: NCT06360289

Locations: 🇫🇷
Centre Hospitalier Universitaire (CHU) Le Kremlin-Bicêtre Assistance Publique-Hôpitaux de Paris (APHP), Paris, Île-de-France, France

Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)

Phase 2

Active, not recruiting

Conditions: Hypertension
High Cardiovascular Risk

Interventions: Drug: Placebo
Drug: Zilebesiran

First Posted Date: 2024-02-22

Last Posted Date: 2025-05-18

Lead Sponsor: Alnylam Pharmaceuticals

Target Recruit Count: 375

Registration Number: NCT06272487

Locations: 🇬🇧
Clinical Trial Site, Pickering, United Kingdom
🇺🇸
Clinical Trial Site 1 - Tomball, Tomball, Texas, United States
🇺🇸
Clinical Trial Site 2 - Tomball, Tomball, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy